947 Shares in Illumina, Inc. (ILMN) Acquired by Comerica Securities Inc.

Comerica Securities Inc. bought a new stake in Illumina, Inc. (NASDAQ:ILMN) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 947 shares of the life sciences company’s stock, valued at approximately $348,000.

Other large investors have also recently modified their holdings of the company. Kaizen Advisory LLC raised its holdings in Illumina by 161.0% in the second quarter. Kaizen Advisory LLC now owns 368 shares of the life sciences company’s stock valued at $103,000 after acquiring an additional 227 shares in the last quarter. Sun Life Financial INC raised its holdings in Illumina by 152.5% in the second quarter. Sun Life Financial INC now owns 399 shares of the life sciences company’s stock valued at $111,000 after acquiring an additional 241 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its holdings in Illumina by 3,192.3% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 428 shares of the life sciences company’s stock valued at $120,000 after acquiring an additional 415 shares in the last quarter. Stratos Wealth Partners LTD. acquired a new stake in Illumina in the third quarter valued at approximately $199,000. Finally, Hall Laurie J Trustee raised its holdings in Illumina by 189.5% in the second quarter. Hall Laurie J Trustee now owns 550 shares of the life sciences company’s stock valued at $154,000 after acquiring an additional 360 shares in the last quarter. 89.90% of the stock is currently owned by hedge funds and other institutional investors.

ILMN stock opened at $329.25 on Friday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.24 and a current ratio of 2.46. Illumina, Inc. has a twelve month low of $203.83 and a twelve month high of $372.61. The company has a market cap of $47.44 billion, a price-to-earnings ratio of 82.31, a P/E/G ratio of 2.40 and a beta of 1.07.

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.26. The business had revenue of $853.00 million for the quarter, compared to analyst estimates of $825.65 million. Illumina had a net margin of 21.09% and a return on equity of 27.10%. The company’s revenue for the quarter was up 19.5% compared to the same quarter last year. During the same period last year, the firm posted $1.11 earnings per share. As a group, analysts predict that Illumina, Inc. will post 5.75 earnings per share for the current year.

A number of analysts have weighed in on the stock. Morgan Stanley raised their price objective on shares of Illumina from $195.00 to $210.00 and gave the stock an “underweight” rating in a report on Friday, July 13th. Piper Jaffray Companies raised their price objective on shares of Illumina from $272.00 to $329.00 and gave the stock an “overweight” rating in a report on Tuesday, July 17th. Canaccord Genuity reissued a “buy” rating and set a $340.00 price objective (up previously from $330.00) on shares of Illumina in a report on Friday, July 27th. Barclays raised their price objective on shares of Illumina from $300.00 to $350.00 and gave the stock an “overweight” rating in a report on Tuesday, July 31st. Finally, Citigroup raised their price objective on shares of Illumina from $330.00 to $345.00 and gave the stock a “buy” rating in a report on Tuesday, July 31st. Six investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $330.94.

In other news, Director Robert S. Epstein sold 1,346 shares of the firm’s stock in a transaction that occurred on Friday, September 7th. The shares were sold at an average price of $345.14, for a total transaction of $464,558.44. Following the transaction, the director now directly owns 7,139 shares in the company, valued at $2,463,954.46. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Jay T. Flatley sold 3,300 shares of the firm’s stock in a transaction that occurred on Wednesday, October 24th. The stock was sold at an average price of $310.58, for a total transaction of $1,024,914.00. Following the transaction, the director now owns 382,304 shares in the company, valued at $118,735,976.32. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 53,464 shares of company stock worth $17,883,331. Insiders own 0.54% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “947 Shares in Illumina, Inc. (ILMN) Acquired by Comerica Securities Inc.” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2018/11/10/947-shares-in-illumina-inc-ilmn-acquired-by-comerica-securities-inc.html.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Further Reading: Swap

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply